Imperva Inc (NYSE:IMPV) issued its earnings results on Thursday, July 27th. The software maker reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by $0.15, Morningstar.com reports. The company had revenue of $74.44 million during the quarter, compared to analyst estimates of $74.30 million. Imperva had a negative net margin of 4.69% and a negative return on equity of 5.00%. The business’s revenue for the quarter was up 28.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.23) EPS. Imperva updated its Q3 guidance to $0.22-0.26 EPS and its FY17 guidance to $0.78-0.82 EPS.
Shares of Imperva (IMPV) opened at 44.60 on Thursday. Imperva has a 12 month low of $34.40 and a 12 month high of $57.24. The company has a 50 day moving average of $47.18 and a 200 day moving average of $45.43. The stock’s market cap is $1.51 billion.
ILLEGAL ACTIVITY WARNING: “Imperva Inc (NYSE:IMPV) Releases Quarterly Earnings Results” was first posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/imperva-inc-nyseimpv-issues-earnings-results-updated-updated/1315155.html.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. purchased a new position in shares of Imperva during the first quarter worth about $102,000. KCG Holdings Inc. purchased a new position in shares of Imperva during the first quarter worth about $201,000. Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Imperva by 26.2% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,177 shares of the software maker’s stock worth $201,000 after buying an additional 866 shares in the last quarter. Amalgamated Bank purchased a new position in shares of Imperva during the second quarter worth about $206,000. Finally, US Bancorp DE boosted its position in shares of Imperva by 142.3% in the first quarter. US Bancorp DE now owns 5,386 shares of the software maker’s stock worth $221,000 after buying an additional 3,163 shares in the last quarter. Hedge funds and other institutional investors own 92.72% of the company’s stock.
IMPV has been the topic of a number of recent analyst reports. BidaskClub lowered shares of Imperva from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 5th. Evercore ISI restated a “buy” rating and issued a $56.00 target price on shares of Imperva in a research note on Monday, May 15th. Monness Crespi & Hardt upped their target price on shares of Imperva from $52.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, May 5th. TheStreet upgraded shares of Imperva from a “d” rating to a “c” rating in a research note on Thursday, May 4th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $47.00 target price on shares of Imperva in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $51.25.
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with our FREE daily email newsletter.